Fig 1.
Patient flow chart of the present study.
Examined subject 1 included a total of 1191 patients to investigate the risk heart failure-related re-hospitalization. Examined subject 2 investigated the effect of continuous administration of Tolvaptan (TLV), and included the 1191 patients from examined subject 1, as well as the patients who received continuous administration of TLV when they were discharged from the hospital (n = 194).
Table 1.
Characteristics of patients.
Fig 2.
Cumulative re-hospitalization risk.
Rates of re-hospitalization for congestive heart failure in the validation subset based on their risk score.
Fig 3.
Calibration plot of the 1-year hospitalization model for worsening of heart failure (external validation).
Table 2.
Univariable and multivariable predictors of 1-year readmission for worsening of heart failure.
Table 3.
The Pretol score.
Fig 4.
Cumulative incidence curves of re-hospitalizations risk.
Cumulative incidence curves of re-hospitalizations risk for worsening of heart failure after 1-year follow-up in the validation subset based on their risk score. Comparison of TLV versus no TLV.